Globus Medical Inc

Surgical & Medical Instruments & Apparatus

GMEDStrong9 of 10 basics passed

$74.10

+1.05%

Market cap $9.95B

$74.10

+1.05%

Market cap $9.95B

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers.

It is a $9.95B healthcare company. Revenue grew 19.7% over the last year, and it keeps 17¢ of every dollar of sales as profit. It trades at 18.7× earnings — near the lowest of its own history.

Website: globusmedical.com
Location: Audubon, PA
Employees: 6 000
Sector: Healthcare

Share price · 3 years

$53.02 → $74.10+39.8%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $3.14B
Profit: keeps 17¢ of every $1 sold; $535M
Free cash flow: cash left after running the business; $756M
P/E: years of profit in the price; 18.7
EPS: earnings per share, TTM; $3.91
Shares: up 42% since 2016 — dilution; 137.1M
Volatility: beta vs the market — under 1 swings less; 0.97

Revenue, last 10 years

52-week range

Low $56.57$74.10High $96.82

Today's price is 44% of the way from the year's low to its high.

P/E vs its history5y

18.7×median 38.7×

Higher than 2% of past days — near the lowest of its own history.

Valuation vs own history

P/E

18.7×

98%

P/S

3.2×

93%

EV/EBITDA

14.4×

87%

P/B

2.1×

77%

FCF yield

7.5%

99%

Share of the last ~5 years that was pricier than today (unusually cheap vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$4.41Mnet selling

Purchases$0

Sales$4.41M

Insiders trading, last 14d0 buy · 0 sell

Standing in Healthcare

Size$9.95Btop 89%
Revenue growth+42%top 6%
Net margin17%top 26%
Return on equity12%top 51%
P/E18.7×top 25%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong valuation, growth and quality.

Valuation85

P/E vs own history2th pct · 25/25
FCF yield7.6% · 20/25
P/S3.2x · 20/25
EV/EBITDA12.4x · 20/25

Growth95

Revenue CAGR32.3% · 25/25
Net income CAGR37.8% · 25/25
EPS CAGR ~5Y31.1% · 25/25
Fwd implied growth25.4% · 20/25

Profitability64

ROIC13.4% · 12/25
ROE11.6% · 12/25
Net margin17.0% · 20/25
Operating margin20.6% · 20/25

Health60

Altman Z9.56 · 25/25
Current ratio4.62 · 25/25
Interest coverage3.5x · 10/25
Net cash / debtn/a · 0/25

Quality95

Piotroski F9/9 · 25/25
Beneish M-2.51 · 25/25
FCF conversion141% · 25/25
Margin stabilityσ 6.5% · 20/25

Moat68

ROIC >12% years3/10 yrs · 6/25
Median gross margin74.6% · 25/25
FCF-positive years10/10 yrs · 25/25
Worst-year net marginworst 4.1% · 12/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2025Financial
Best year on record
$538M net income
FY2022Financial
Revenue crossed $1B
$1.02B for the year
FY2016Financial
Profitable every year on record
10 consecutive profitable years in our data
FY2016Financial
Positive free cash flow every year since
10-year streak

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$9 124 today — price return only

$2.9B revenue in FY2025

Revenue up 19.7% year over year

Profitable 10 years in a row

Positive free cash flow 10 years in a row

6 000 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (68.5%)
Revenue growing 19.7% year over year
Strong cash conversion — FCF is 24.0% of revenue
Piotroski F-Score 9/9 — fundamentally strong checklist
Altman Z-Score 9.56 — low bankruptcy-risk zone

Watch-outs

Nothing stands out as a concern in the available data.

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

9 of 10 checks passed

Revenue growing — the company sells more than a year ago+19.7% YoY
Profitable — makes more than it spends$535M TTM
Profit growing — earnings are higher than last year+28.4% YoY
Generates cash — cash left after running and investing$756M TTM
Debt under control — could handle its obligationscurrent ratio 4.62
Established company — not a micro-cap — lower blow-up risk$9.95B market cap
Not printing shares — share count not ballooning — you keep your slice+35.7% shares over ~5y
Proven track record — years of profitability behind it10/10 profitable years
Financially stable — balance sheet not near distressAltman Z 9.6 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsP/E 18.7

Peer comparisonGlobus Medical Inc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
GMED this company	$9.9B	18.7	+19.7%	17.0%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: GMED vs LLY · GMED vs JNJ · GMED vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 4Buy 12Hold 7

Appendix · Financial records

The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $3.14B · net income $535M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$3.14B

YoY 19.7%

Net income (TTM)

$535M

Margin 17.0%

Gross margin

68.5%

Operating margin

20.6%

P/E ratio

18.7

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.8	1.0	1.0	1.6	2.5	2.9
Gross profit	0.6	0.7	0.8	1.0	1.5	2.0
Operating income (EBIT)	0.1	0.2	0.2	0.1	0.2	0.5
Net income	0.1	0.1	0.2	0.1	0.1	0.5
EPS (diluted)	1.01	1.44	1.85	1.07	0.75	3.92

Cash flowFree cash flow $756M · operating cash flow $910M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$756M

Margin 24.0%

Operating cash flow (TTM)

$910M

FCF margin

24.0%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	0.2	0.3	0.2	0.2	0.5	0.8
Capital expenditure	-0.1	-0.1	-0.1	-0.1	-0.1	-0.2
Free cash flow	0.1	0.2	0.1	0.2	0.4	0.6
FCF margin	17.1%	22.9%	10.2%	10.5%	16.1%	20.0%

Balance sheetAssets $5.30B · debt n/a (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $5.30B of assets is financed

86%

Liabilities $730M — borrowed moneyEquity $4.57B — owners' stake

Altman Z-Score

9.56

Safe zone

Debt repayment

0.0 yrs

Years of free cash flow to clear net debt

Interest coverage

3.5x

EBIT ÷ interest expense

ROE

11.6%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.2	0.3	0.3	0.1	0.1	0.6
Total assets	1.7	2.0	2.1	5.1	5.3	5.3
Total liabilities	0.2	0.2	0.2	1.1	1.1	0.7
Total debt	—	—	—	—	—	—
Equity	1.5	1.7	1.8	4.0	4.2	4.6
Net debt	—	—	—	—	—	—

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of GMED on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $74.10 · market cap $9.95B.